Drug Trial Radar · NCT04179604
Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS)
Last checked: Nov 19, 2026Latest source record: Jul 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Jun 17, 2020
Primary completion
Jan 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- María de los Ángeles Tena PajueloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Orion Corporation, Orion Pharma; Canary Foundation; Hospital Universitario de Gran Canaria Doctor Negrín; CRO TRIDE Asesores SL; QBE Europe SA/NV
- First posted
- Nov 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Low cardiac output Syndrome (LCOS) is a complication that appears in approximately 20% of cardiac surgeries with extracorporeal circulation. LCOS is associated with increased mortality, delayed recovery and prolonged hospital stay. The Spanish Randomized Clinical Trial on Levosimendan (brand name: Sindax) (SPARTANS) aims to demonstrate the effectiveness of the preoperative use of Levosimendan in reducing LCOS in patients with poor left ventricle ejection fraction (LVEF) undergoing elective cardiac surgery. SPARTANS study is a multicenter, randomized triple-blind, placebo-controlled trial. 300 patients with LVEF ≤ 35%, undergoing elective cardiac surgery will be recruited from 9 Spanish hospitals and randomized into two groups: Preoperative administration of levosimendan or placebo for 24 hours. The study drug will be started as a continuous infusion (0.1 µg/kg/min) at least 8 hours before surgery to complete 24h duration. The primary endpoint will be 30-day LCOS. It will be evaluated using any of the following criteria: 1\) postoperated cardiac index ≤2.0 L / min / m2, 2) a need to implant a intra-aortic balloon pump/ left ventricular assist device, 3) a vasoactive inotropic scale (VIS) \> 5.5. The secondary end-point will be composite event rate at one year including any of the following events: death from any cause, need for renal replacement therapy or dialysis and LCOS. The sample size is based on the assumption that levosimendan reduces LCOS by 50% being necessary a sample size of 300 patients to carry out the study. The Research Team of each hospital, will carry out the clinical follow-up by telephone or clinical interview of the patient according to the time intervals: 30 days and 1 year. We estimate that the total sample size of 300 patients will be reached in 2-2.5 years. In conclusion, the effectiveness of levosimendan has not yet been reported with a good evidence in cardiac surgery. The purpose of the "Spanish Randomized Clinical Trial on Sindax" (SPARTANS) trial is to evaluate the beneficial effect of preoperative use of levosimendan compared with placebo to reduce perioperative LCOS in patients undergoing cardiac surgery with poor LVEF ≤ 35%.
Conditions
- Cardiac Output, Low
Interventions
LevosimendanDrug
Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
PlacebosDrug
Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with LCOSTime frame: up to 30 days of cardiac surgery
- Number of Participants with LCOSTime frame: up to 30 days of cardiac surgery
- Number of Participants with LCOSTime frame: up to 30 days of cardiac surgery
- Number of Participants with LCOSTime frame: up to 30 days of cardiac surgery
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
A coruña UNIVERSITY HOSPITAL COMPLEX A CORUÑA
A Coruña, Spain · Recruiting
12 de Octubre University Hospital
Madrid, Spain · Not yet recruiting
Virgen Macarena University Hospital
Seville, Spain · Recruiting
Valladolid universitary Hospital
Valladolid, Spain · Recruiting
GERMANS TRIAS I PUJOL DE BADALONA university Hospital
Badalona, Barcelona, Spain · Not yet recruiting
Doctor Josep Trueta university Hospital
Girona, Gerona, Spain · Not yet recruiting
Doctor Negrin University Hospital
Las Palmas de Gran Canaria, Gran Canarias, Spain · Recruiting
Puerta del Hierro University Hospital
Majadahonda, Madrid, Spain · Not yet recruiting
Virgen de la Victoria University Hospital
Málaga, Malaga, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.